Skip to content

Treatment of Throat Irritation with Unani Medicine Qurse-Tabasheer Mulaiyin.

A single-arm, multicentre, clinical validation study to Evaluate the Safety and Efficacy of a Unani Pharmacopoeial formulation, Qurs-e-Tabasheer Mulaiyin in Khushanat-i-Halq (Irritation of Throat) - NILL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099551
Enrollment
220
Registered
2025-12-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J02- Acute pharyngitis

Interventions

Intervention1: Qurs-e-Tabasheer Mulaiyin: 2 Tab Twice daily taken orally with lukewarm water for 14 days. Control Intervention1: NIL: NIL

Sponsors

Central Council for Research in Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having Throat irritation with or without any of the following symptoms: 1. Hoarseness of voice 2. Dysphagia 3. Cough 4. Pharyngeal erythema 5. Pain in throat 6. Post nasal drip

Exclusion criteria

Exclusion criteria: 1. Known cases of fungal and bacterial pharyngitis. 2. Patients with all classic symptoms of Group A Streptococcal Pharyngitis: i. Red and swollen tonsils ii. Tonsillar exudates (white patches /streaks of pus) iii. Swollen, tender anterior cervical lymph nodes iv. Absence of cough 3. High grade fever 4.Known cases of Epiglottises. 5. Known cases of Oral candidiasis. 6. Known cases of Herpes simplex. 7.Known cases of Renal or Hepatic or Cardiac ailments. 8.Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Improvement in the signs and symptoms of Khushunat-e-Halaq (Irritation of Throat). Which will be assessed on the basis of the VAS score.Timepoint: At baseline, first follow up and at the end of treatment. (i.e., 0, 7th and 14th day)

Secondary

MeasureTime frame
Haematological and biochemical investigations for safety assessment i.e.,Haemogram, AEC, LFT, KFT, CRP and Urine R/M.Timepoint: At baseline, first follow up and at the end of treatment. i.e., 0, 7th and 14th day

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

younismunshi@gmail.com09419086700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026